<div><div></div><div><span><p><span>Incannex Healthcare Inc. reported first-quarter 2026 results with revenue of $0.09M and a net loss of $3.88M, or diluted EPS of $(0.35), compared with a net loss of $3.97M and diluted EPS of $(6.19) in the year-ago quarter.</span></p><p><strong><span>Financial Highlights</span></strong></p><ul><li><span>Revenue was $0.09M for the quarter ended Mar 31, 2026, versus $0.00M in the year-ago quarter.</span></li><li><span>Net income was a loss of $3.88M for the quarter ended Mar 31, 2026, versus a loss of $3.97M in the year-ago quarter.</span></li><li><span>Diluted EPS was $(0.35) for the quarter ended Mar 31, 2026, versus $(6.19) in the year-ago quarter.</span></li></ul><p><strong><span>Business Highlights</span></strong></p><ul><li><span>Clinical pipeline advanced: Phase 2 dose-optimization for IHL-42X (obstructive sleep apnea) and Phase 2b dose-comparison for PSX-001 (generalized anxiety disorder).</span></li><li><span>Regulatory progress: IHL-42X granted FDA Fast Track designation; IND approval obtained for PsiGAD2 to support U.S. and U.K. Phase 2b trials.</span></li><li><span>R&amp;D spending shifted: R&amp;D expense declined following completion of an IHL-42X safety/pharmacokinetics trial, with R&amp;D expected to increase as the DReAMzz program advances.</span></li><li><span>Capital actions: Raised approximately $10M in a March 2026 registered direct offering and executed share repurchases while maintaining a cash runway in excess of one year.</span></li><li><span>Partnerships: Continued investment in the Mind Clinics Australia joint venture to support clinical and operational expansion.</span></li></ul><p><span>Original SEC Filing: </span>Incannex Healthcare Inc. [ IXHL ] - 10-Q - May. 15, 2026</p><section><b><span class="heading-JaE7wgR2">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

IXHL

<p>Incannex Healthcare Inc. reported Q1 2026 revenue of $0.09M and a net loss of $3.88M, with diluted EPS of $(0.35). This compares to a net loss of $3.97M and EPS of $(6.19) in the previous year. The company advanced its clinical pipeline, received FDA Fast Track designation for IHL-42X, and raised approximately $10M in a direct offering while maintaining a cash runway over one year.</p>

TradingView

Incannex Healthcare

iShares Global Healthcare

SPDR S&P Biotech

iShares Biotechnology ETF

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

iShares US Pharma

VanEck Biotech ETF

VG Health

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

Incannex Healthcare Inc. 1Q 2026: Revenue $0.09M, EPS $(0.35) — 10-Q Summary